je.st
news
Tag: therapy
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer
2015-03-05 00:30:00| Merck.com - Product News
Dateline City: TOKYO & KENILWORTH, N.J. Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, through a subsidiary, announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Mercks anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the brand name KEYTRUDA), in combination with Eisai oncology compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed in the U.S. Language: English Contact: Eisai Public Relations Department+81-(0)3-3817-5120orEisai Investor Relations+81-(0)3-3817-5327orMerck Media RelationsPamela Eisele, 267-305-3558or Claire Mulhearn, 908-236-1118orMerck Investor RelationsJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Varian Medical Systems to Equip National Center for Proton Therapy in Denmark
2015-02-20 11:31:25| Industrial Newsroom - All News for Today
PALO ALTO, Calif. Varian Medical Systems (NYSE: VAR) today announced that it has been selected to equip and service a new national proton therapy center in Aarhus, Denmark, with the Varian ProBeam proton therapy system. Under a completed public tender, Varian was selected to provide equipment, software and...
Tags: center
national
systems
medical
Genzyme's $845 pact with Voyager will advance gene therapy
2015-02-11 22:40:06| Biotech - Topix.net
In a deal reminiscent of Genzyme's $700 million collaboration with Cambridge neighbor Alnylam Pharmaceuticals a year ago, the rare drug giant today announced a deal worth up to up to $845 million with gene therapy startup Voyager Therapeutics. The agreement between 35-employee Voyager, located on Sydney Street in Cambridge, came out of a natural overlap between what the two companies have been working on, according to Mark Barrett , Genzyme's vice president of Strategy & Business Development for Rare Diseases.
Tags: advance
therapy
gene
voyager
UnitedHealth-backed Orthology buys Twin Cities physical therapy group
2015-02-06 00:51:16| Beverages - Topix.net
Orthology didn't disclose terms of its deal to buy Reynolds Rehabilitation Enterprises Inc., which operates clinics in Minneapolis and Eagan. Orthology treats patients suffering from athletic injuries and chronic pain.
Tags: group
physical
cities
therapy
FDA Grants Breakthrough Therapy Designation To LentiGlobin For Treatment Of Beta-Thalassemia Major
2015-02-04 06:25:44| drugdiscoveryonline Home Page
bluebird bio, Inc. a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases, recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LentiGlobin BB305 Drug Product for the treatment of transfusion-dependent patients with beta-thalassemia major
Tags: major
treatment
therapy
grants
Sites : [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] next »